{"type":"trials","record":{"id":87180,"source_id":"isrctn","external_id":"ISRCTN73359806","title":"Bevacizumab versus ranibizumab in age-related macular degeneration","brief_summary":"Monotherapy with bevacizumab is as effective as monotherapy with ranibizumab for the treatment of exudative age-related macular degeneration (AMD).","overall_status":"Completed","phases":[],"study_type":"Interventional","sponsor":"VA Boston Healthcare System (USA)","enrollment":125,"countries":["United States of America"],"start_date":"2007-04-07","completion_date":"2010-04-07","last_update_date":"2009-12-17","source_url":"https://www.isrctn.com/ISRCTN73359806","editorial_summary":"A registered study indexed because it matched monitored longevity research terms. Registry status: Completed. Registration does not establish safety or effectiveness.","first_seen_at":"2026-09-25T03:46:39.792962+00:00","last_seen_at":"2026-09-25T03:46:39.551+00:00","metadata":{"sex":"All","age_range":"Senior","comparator":null,"attribution":"Source: ISRCTN ISRCTN73359806; retrieved 2026-09-25","interventions":["Bevacizumab, ranibizumab","Drug"],"reuse_license":"Registry contribution CC BY 4.0; generated metadata CC0","registry_source":"ISRCTN","outcome_measures":["Visual acuity, measured at 6 months and one year","1. Central foveal thickness, measured at 6 months and one year 2. Quality of life assessment, measured at one year"],"design_description":"Interventional","source_has_results":false},"controlled_terms":["Age-related macular degeneration","Intravitreal injection with ranibizumab or bevacizumab based on random allocation. Dosage: Ranibizumab 0.5 mg/0.05 ml,…","results","Bevacizumab, ranibizumab","Drug"],"relevance_confidence":100,"source_quality_score":98,"freshness_score":35,"publication_state":"published","match_explanation":"Title contains controlled term: age-related macular degeneration.","quality_checked_at":"2026-09-25T03:46:42.633202+00:00","duplicate_cluster_key":"id:isrctn73359806","duplicate_of_id":null,"evidence_snapshot":{"status":"structured","version":1,"duration":"2007-04-07 to 2010-04-07","comparator":null,"confidence":"structured-source","population":"All · Senior","provenance":{"duration":"start_date and completion_date","comparator":"registry arm fields","population":"registry eligibility fields","intervention":"registry intervention fields","participants":"enrollment","study_design":"study_type and registry design fields","evidence_stage":"phases","reported_outcome":"not available","outcomes_measured":"registry outcome-measure fields"},"generated_at":"2026-09-25T03:46:39.593Z","intervention":["Bevacizumab, ranibizumab","Drug"],"participants":125,"study_design":"Interventional","subject_scope":"Human clinical study registration","evidence_stage":"Phase not reported","safety_context":"Eligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians.","source_support":"Structured registry protocol metadata; no finding-level conclusion is generated.","main_limitation":"This is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.","reported_outcome":null,"outcomes_measured":["Visual acuity, measured at 6 months and one year","1. Central foveal thickness, measured at 6 months and one year 2. Quality of life assessment, measured at one year"],"regulatory_context":"Trial registration is not regulatory approval and does not establish that an intervention is available."},"clinical_trial_topics":[{"topic_slug":"vision-aging","is_published":true,"match_reasons":["Title contains controlled term: age-related macular degeneration.","Abstract contains controlled term: age-related macular degeneration.","Source terminology contains: age-related macular degeneration.","Title supplies longevity context: age-related.","Study type is explicitly identified as Interventional."],"matched_fields":["title","abstract","controlled terminology","title context","study type"],"relevance_score":100,"intelligence_topics":{"name":"Vision ageing","slug":"vision-aging"}}],"content_sources":{"name":"ISRCTN Registry","homepage_url":"https://www.isrctn.com/"}},"canonical_url":"https://www.immortal.life/trials/87180","automation_disclosure":"Generated automatically from cited source metadata. No scientist, clinician, researcher, editor, or human reviewer evaluates this publication before release."}